Ekin Ezgi Cesur

Dr. Ekin Ezgi Cesur


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KÖKadir Burak Özer
Kadir Burak Özer
SESuat Erus
Suat Erus
ECEkin Ezgi Cesur
Ekin Ezgi Cesur
ÖGÖzgür Güzey
Özgür Güzey
PBPınar Bulutay
Pınar Bulutay
ŞDŞükrü Dilege
Şükrü Dilege
Background/Objectives: Despite advances in the TNM staging system, prognostic heterogeneity persists in early-stage non-small cell lung cancer (NSCLC). Lymphatic invasion (LI) is a known marker of aggression, but its independent significance in the critical, low-risk Stage I, N0 subgroup—typically ineligible for adjuvant therapy—remains poorly defined. We hypothesized that LI acts as a powerful, yet hidden, risk factor in this highly favourable cohort. Methods: This retrospective cohort study included 988 consecutive patients who underwent curative anatomical resection for NSCLC. All patients underwent complete resection with pathologically confirmed negative surgical margins (R0 resection). Cases were staged according to the 9th Edition of the TNM Classification of Malignant Tumours (TNM-9) and grouped as LI-positive or LI-negative. A critical subgroup analysis focused on 347 truly low-risk patients (TNM Stage I, N0, no vascular or pleural invasion). Overall survival (OS) was evaluated using the Kaplan–Meier method and multivariable Cox proportional hazards models. Results: In the entire cohort (n = 988), LI was present in 40.9% of cases. LI positivity was an independent predictor of worse OS in multivariable analysis (HR: 1.520, 95% CI: 1.004–2.301, p = 0.048). In the low-risk subgroup (n = 347), the presence of LI resulted in a drastic survival divergence, with 5-year OS declining from 96.1% (LI-negative) to 83.8% (LI-positive). Multivariable analysis confirmed LI as an independent adverse prognostic factor in this subgroup (HR: 4.002, 95% CI: 1.567–10.221, p = 0.004). Conclusions: Lymphatic invasion is a robust, independent adverse prognostic factor in resected NSCLC. LI may identify a subset of early-stage N0 NSCLC patients who warrant closer postoperative surveillance and prospective evaluation for adjuvant treatment strategies. Validation in prospective cohorts is required before LI can be formally integrated into staging algorithms or treatment guidelines.

16 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EKEmine Karabul
Emine Karabul
SESuat Erus
Suat Erus
ECEkin Ezgi Cesur
Ekin Ezgi Cesur
KÖKadir Burak Özer
Kadir Burak Özer
Yuksel PekerYuksel Peker
Yuksel Peker
Background: Sleep and mood disturbances are common in patients with cancer, but their prevalence, co-occurrence, and associated factors remain insufficiently characterized in patients undergoing surgery for primary lung cancer. Methods: This cross-sectional study included 69 patients with primary lung cancer evaluated before surgery. Obstructive sleep apnea (OSA) risk was assessed using the Berlin Questionnaire, insomnia using the Insomnia Severity Index (ISI), restless legs syndrome (RLS) symptoms using a standardized screening questionnaire, anxiety using the Beck Anxiety Inventory, and depressive symptoms using the Zung Self-Rating Depression Scale. Daytime sleepiness and functional outcomes were evaluated using the Epworth Sleepiness Scale and Functional Outcomes of Sleep Questionnaire, respectively. Multivariable logistic regression was used to identify factors associated with insomnia symptoms. Results: Insomnia symptoms (ISI ≥ 8) were present in 44.9% of patients, including 13.0% with moderate-to-severe insomnia symptoms (ISI ≥ 15). A high OSA screening risk was identified in 33.3%, and RLS symptoms in 21.7%. Moderate-to-severe anxiety symptoms were present in 18.8%, and moderate-to-severe depressive symptoms in 30.9% (21/68). Coexisting insomnia symptoms and a high OSA screening risk were observed in 18.8% of patients. Anxiety scores were higher among patients with insomnia symptoms. In multivariable analysis (n = 68), higher Beck Anxiety Inventory scores were associated with insomnia symptoms after adjustment for age, sex, and depressive symptom severity (adjusted odds ratio 1.12 per point; 95% CI 1.04–1.21; p = 0.004). Among patients with available functional outcome data (n = 60), greater insomnia severity, anxiety symptoms, and daytime sleepiness were associated with poorer sleep-related daytime functioning. Conclusions: Sleep disturbances and psychological symptoms were common before primary lung cancer surgery and frequently co-occurred. Anxiety symptom severity was associated with insomnia symptoms after adjustment for demographic factors and depressive symptom severity. These findings suggest the potential value of integrated preoperative assessment of sleep and psychological symptoms, although further studies are needed to establish its clinical benefits.

23 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
CECaglayan Selenge Beduk Esen
Caglayan Selenge Beduk Esen
SSSukran Senyurek
Sukran Senyurek
DSDuygu Sezen
Duygu Sezen
FSFatih Selcukbiricik
Fatih Selcukbiricik
KKKerim Kaban
Kerim Kaban
USUgur Selek
Ugur Selek
Purpose/Objective: To evaluate the safety and failure patterns of consolidative hypofractionated thoracic radiotherapy (RT) following induction chemoimmunotherapy in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). Materials/Methods: This retrospective study included 34 patients treated between 2019 and 2025. All patients received induction chemoimmunotherapy followed by consolidative hypofractionated RT based on multidisciplinary tumor board recommendations. The primary endpoint was local recurrence (LR); secondary endpoints were regional recurrence (RR), distant metastasis (DM), overall survival (OS), progression-free survival (PFS), and treatment-related toxicity. Results: Median age was 64 years, and median PD-L1 expression was 20%. Most patients had stage III disease; squamous cell carcinoma (56%) and adenocarcinoma (38%) were the predominant histologies. The most common systemic regimen was carboplatin/paclitaxel plus nivolumab, with a median of four induction cycles. Post-induction response was complete in 21%, partial in 62%, stable in 12%, and progressive in 6%. Median RT dose was 52.5 Gy in 15 fractions, and maintenance immunotherapy was administered in 79%. At a median follow-up of 16.7 months, using cumulative incidence functions with death treated as a competing event, the 1- and 2-year cumulative incidences of local failure were 6.9% and 14.7%, respectively. The corresponding cumulative incidences of regional failure were 10.2% and 18.8%, while distant metastasis incidences were 15.9% and 39.2%. No isolated local or regional recurrences occurred. One- and two-year OS rates were 86% and 81%, and corresponding PFS rates were 76% and 54%. No grade 4–5 RT-related toxicity occurred; one grade 5 immune-related pneumonitis was observed. Conclusions: Consolidative hypofractionated RT following chemoimmunotherapy appears feasible and associated with favorable outcomes, supporting further prospective investigation.